[July 21, 2015]

Research and Markets: Malignant Mesothelioma Therapeutics Pipeline Report 2015 - 50 Companies & 64 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/vbsxvj/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strngthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Aduro BioTech, Inc.
• Advantagene, Inc.
• Aeolus Pharmaceuticals, Inc.
• Amphera BV
• Applied Research using OMIC Sciences, S.L.
• arGEN-X BV
• ArQule, Inc.
• AVEO Pharmaceuticals, Inc.
• Bayer AG
• Biogen, Inc.
• Bionomics Limited
• Biotecnol, Inc.
• Boehringer Ingelheim GmbH
• Boston Biomedical, Inc.
• Bristol-Myers Squibb Company
• Calithera Biosciences, Inc.
• CanBas Co., Ltd.
• Concordia Healthcare Corp.
• CritiTech, Inc.
• Deciphera Pharmaceuticals, LLC
• Eagle Pharmaceuticals, Inc.
• Eisai Co., Ltd.
• Eli Lilly and Company
• EnGeneIC Ltd
• F. Hoffmann-La Roche Ltd.
• Five Prime Therapeutics, Inc.
• Formula Pharmaceuticals, Inc.
• Genelux Corporation
• GlaxoSmithKline plc
• Juno Therapeutics Inc.
• Kyowa Hakko Kirin Co., Ltd.
• MedImmune, LLC
• Merck & Co., Inc.
• Merck KGaA
• Millennium Pharmaceuticals, Inc.
  

For more information visit http://www.researchandmarkets.com/research/vbsxvj/malignant

View source version on businesswire.com: http://www.businesswire.com/news/home/20150721006151/en/

[ Back To TMCnet.com's Homepage ]